Skip to content

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Telemedicine vs. Face-to-Face Cancer Genetic Counseling in Rural Oncology Clinics

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00609505
Enrollment
130
Registered
2008-02-07
Start date
2008-08-31
Completion date
2011-04-30
Last updated
2012-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome

Keywords

Hereditary Breast and Ovarian Cancer syndrome, genetic counseling, breast cancer, ovarian cancer, telemedicine, Cancer genetic counseling

Brief summary

Cancer genetic counseling (CGC) has been found to have substantial benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as standard of care for women with breast cancer and their relatives. Unfortunately, there is a disparity in access to CGC, especially among women who live in rural and underserved areas. In North Carolina, only two cancer genetic counselors practice in rural clinics - each only for a few days per month. Therefore, in an effort to make CGC more widely available in a timely manner, we propose to test provision of counseling through telemedicine (TM), in which a patient and health care provider communicate with each other using videoconferencing. In 4 rural oncology clinics, we will implement low-cost TM and compare satisfaction and cost-effectiveness between groups of women designated to have their CGC session by TM or FTF. We'll use a validated measure to assess satisfaction by a phone survey one week after the CGC appointment; cost-effectiveness will be measured at project's end by calculating length of wait time for appointment and costs of equipment, labor, and mileage. Study hypothesis: TM is as satisfactory as FTF counseling and is a more cost-effective way to provide this beneficial service.

Interventions

OTHERTelemedicine

Telemedicine genetic counseling

Face-to-face genetic counseling

Sponsors

Susan G. Komen Breast Cancer Foundation
CollaboratorOTHER
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals referred for cancer genetic counseling (e.g., by medical oncologist, primary care physician or self) in one of 4 oncology clinics: Gibson Cancer Center in Lumberton, NC; Scotland Cancer Treatment Center in Laurinburg, NC; Johnston Cancer Center in Smithfield, NC; and Maria Parham Cancer Center in Henderson, NC. * Willing to be randomized to receive counseling via telemedicine or face-to-face.

Exclusion criteria

* Referred for cancer genetic counseling from any clinic other than the 4 listed above. * Unwilling to be randomized to receive counseling via telemedicine or face-to-face.

Design outcomes

Primary

MeasureTime frame
Patient satisfactionOne week post-intervention (genetic counseling session)

Secondary

MeasureTime frame
Cost-effectivenessEnrollment completion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026